Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of brentuximab vedotin monotherapy in relapsed/refractory CD30-positive peripheral T-cell lymphoma
2013-003946-17Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Sep 2014
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in peripheral T-cell lymphoma (PTCL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: overall objective response rate. Started Sep 2014; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on 2013-003946-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003946-17.